Background-Stroke risk in atrial fibrillation (AF) using oral vitamin K antagonists is closely related to bleeding risk. The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR [international normalized ratio], elderly, drugs/alcohol concomitantly) bleeding score has demonstrated usefulness in assessing major bleeding risk in patients with AF. However, risk factors for warfarin-associated bleeding also predict stroke risk in patients with AF. We tested the usefulness of the HAS-BLED score for predicting both major bleeding and cardiovascular events in a cohort of anticoagulated patients with AF. Methods and Results-We recruited 965 consecutive anticoagulated outpatients with permanent or paroxysmal AF who were stabilized for at least 6 months on oral anticoagulation (international normalized ratio, 2.0 -3.0). Medical history and HAS-BLED score were assessed. Cox regression models were used to determine the association between clinical risk factors and bleeding episodes, adverse cardiovascular events, and mortality. 
boembolism, such as advanced age, uncontrolled hypertension, history of ischemic heart disease, cerebrovascular disease, or previous bleeding events, have also been identified as risk factors for bleeding. 7 In clinical practice, estimation of both stroke and bleeding risks are essential to guide the selection of the most appropriate thromboprophylactic measures. 8, 9 To assess bleeding risk, many clinical factors have been incorporated into risk stratification schemes, but up to now, they have been based on complex scoring systems and, therefore, are difficult to apply in daily decision-making. 10 More recently, the European and Canadian guidelines 8, 9 for AF management have recommended use of the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR [international normalized ratio], elderly, drugs/alcohol concomitantly) bleeding risk score to assist in estimating major bleeding risk in patients with AF. 11 The HAS-BLED score has recently been validated in a large anticoagulated trial population. 12 In the context of clinical trials, patients often are carefully selected, whereas patients with AF in real-life clinical practice tend to be older with associated comorbidities and polypharmacy, factors that may make accurate estimation of stroke and bleeding risk more difficult. The aim of our study was to evaluate the clinical usefulness of the HAS-BLED score in a large cohort of stable patients with AF on long-term anticoagulation for assessing major bleeding episodes as well as other adverse events, including all-cause mortality and cardiovascular mortality.
Methods

Patients
We recruited consecutive patients with permanent or paroxysmal AF on OAC from our outpatient anticoagulation clinic. To homogenize the cohort of patients, only patients who had an INR between 2.0 and 3.0 during the previous 6 months of clinic visits were included, so the time of therapeutic range (TTR) of this period was Ϸ100%. All patients were anticoagulated with acenocoumarol. Patients with prosthetic heart valves, acute coronary syndrome, stroke (ischemic or embolic), valvular AF, or any hemodynamic instability as well as patients who had hospital admission or surgical intervention in the preceding 6 months were excluded from the study. A history of malignancy was allowed if the patient's expected survival duration was Ͼ6 months and the patient was not receiving chemotherapy or radiotherapy at study entry. A complete medical history was recorded. Follow-up was performed through visits to the anticoagulation clinic.
The HAS-BLED bleeding risk score was calculated as a measure of baseline bleeding risk, as the result of adding 1 point to hypertension, abnormal renal and liver function (1 point each), stroke, bleeding history or predisposition, labile INR, old age (Ն65 years), and use of drugs and alcohol concomitantly (1 point for each). Based on the inclusion criteria at entry, labile INR was quantified as 0 in every patient. Baseline stroke risk was assessed using the CHADS 2 (congestive heart failure, hypertension, age Ͼ75, diabetes mellitus, and prior stroke or TIA [ 8, 9 Adverse cardiovascular end points (mainly thromboembolic) were defined as stroke/TIA, peripheral embolism, acute coronary syndrome, acute heart failure, and cardiac death. Bleeding events were assessed by the 2005 International Society on Thrombosis and Haemostasis criteria. 13 The definitions were as follows: fatal or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, or bleeding causing a fall in hemoglobin level of Ն20 g/L (1.24 mmol/L) or leading to transfusion of Ն2 units of whole blood or red cells. Finally, we recorded all-cause mortality and whether the cause of death was secondary to a cardiovascular end point (stroke/TIA, peripheral embolism, acute coronary syndrome, acute heart failure, and cardiac death) or a hemorrhagic event. 
Statistical Analysis
Results
We included 965 patients (men, 50%; median age, 76 years [interquartile range, 70 -81 years]) ( Table 1 ). The median CHADS 2 risk score was 2 (interquartile range, 2-3), and 77% of patients had a CHADS 2 risk score of Ն2. The median CHA 2 DS 2 -VASc score was 4 (3-5), and 94% had a CHA 2 DS 2 -VASc score Ն2. The median HAS-BLED score was 2 (2-3), and 29% of patients had an HAS-BLED score Ն3.
Median follow-up was 861 days (range, 718 -1016 days). During this period, 103 patients (4.9%/y) experienced an adverse cardiovascular event, for whom 37 (1.8%/y) were strokes, 37 (1.8%/y) were acute coronary syndrome, and 27 (1.4%/y) were acute heart failure. During the same period, 75 patients (3.6%/y) presented with a hemorrhagic event; of these, 15 (0.70%/y) were intracranial hemorrhages. Ninetyfive (4.5%/y) patients died during the follow-up, 28 (1.3%/y) of whom as a result of a thrombotic event and 8 (0.4%/y) of whom as a result of a hemorrhagic event.
Relation of Major Events to HAS-BLED Score
The incidence of both bleeding and adverse cardiovascular events was higher with increasing HAS-BLED score (Figure) . Annual bleeding rates only exceeded thrombotic events at an HAS-BLED score Ͼ3 and were statistically significant for an HAS-BLED score Ͼ4 (PϽ0.05).
Univariate Analysis
On unadjusted (crude) analyses, the HAS-BLED score was predictive for major bleeding events as a continuous variable (hazard ratio [ 
Multivariate Analysis
Using a Cox regression analysis, independent predictors for major bleeding were age Ͼ75 years (Pϭ0.03), male sex (Pϭ0.036), renal impairment (Pϭ0.01), previous bleeding episode (PϽ0.001), current alcohol consumption (Pϭ0.043), and concomitant malignant disease (Pϭ0.020) ( Table 2) . Independent predictors for adverse cardiovascular events were age Ͼ75 years (Pϭ0.001), history of heart failure (Pϭ0.004), and previous stroke (Pϭ0.005) ( Table 3 ). Finally, independent predictors for all-cause mortality, were age Ͼ75 years (PϽ0.001), diabetes (Pϭ0.025), previous stroke (Pϭ0.034), heart failure (Pϭ0.027), current smoking (PϽ0.001), and concomitant malignant disease (PϽ0.001) ( Table 4) .
Predictive Value for Bleeding, Cardiovascular Events, and Death
The HAS-BLED score had a C statistic for bleeding of 0.70 (95% CI, 0.64 -0.76; PϽ0.001), whereas for adverse cardiovascular events, the C statistic was 0.58 (95% CI, 0.52-0.64; Pϭ0.006); for all-cause mortality, the C statistic was 0.62 (95% CI, 0.56 -0.67; PϽ0.001). Using statistical models with significant variables (but not including the HAS-BLED or CHADS 2 scores), the multivariate analysis gave a C statistic for bleeding of 0.75 (95% CI, 0.73-0.78), whereas for adverse cardiovascular events, the C statistic was 0.66 (95% CI, 0.63-0.69); for all-cause mortality, the C statistic was 0.77 (95% CI, 0.75-0.80).
Discussion
In this study, we show for the first time to our knowledge that the HAS-BLED score not only is useful in the assessment of bleeding risk, but also has some predictive value for cardiovascular events and mortality in anticoagulated patients with AF. We confirm previous observations on the predictive value of the HAS-BLED score for major bleeding 11, 12 and show that bleeding rates only exceeded thrombotic events at a HAS-BLED score Ͼ3. Finally, we have validated the HAS-BLED score for the first time, to our knowledge, in consecutive patients taking acenocoumarol (rather than warfarin) as their OAC medication.
HAS-BLED Predicts Bleeding Events
Patients with AF are at high risk of both cardiovascular and hemorrhagic events, as we show in this article and have previously described. 14 Common comorbidities such as diabetes, hypertension, chronic heart failure, and cardiac valve disease were independent risk factors for AF, 15 but such risk factors are also well recognized for stroke and thromboem- Data are presented as n (%) or median (interquartile range). TIA indicates transient ischemic attack; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR ͓interna-tional normalized ratio͔, elderly, drugs/alcohol concomitantly; CHADS 2 , congestive heart failure, hypertension, age Ն75, diabetes mellitus, and prior stroke or TIA; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker. bolism as well as for cardiovascular events. Indeed, many risk factors for stroke are also associated with a higher risk for anticoagulation-associated hemorrhage. 10 Thus, bleeding risk increases with increasing CHADS 2 score, and Hylek et al, 6 for example, clearly described that the rate of major hemorrhage was substantially higher in patients with CHADS 2 scores Ն3. Similarly, in another cohort of elderly patients, a history of stroke (which confers a minimum CHADS 2 score of 2) was associated with a high risk for bleeding when taking OAC medication. 16 In a systematic review, some patient characteristics such as advanced age, uncontrolled hypertension, history of ischemic heart disease, cerebrovascular disease, anemia, or history of bleeding and the concomitant use of other drugs such as antiplatelet agents are identified as risk factors for anticoagulation-related bleeding complications. 7 The present study also identifies advanced age, male sex, renal impairment, history of bleeding, current alcohol consumption, and malignancy as independent risk factors for bleeding in this cohort. Of note, sex was not identified in the systematic review for the UK-National Institute for Health and Clinical Excellence clinical practice guidelines and the HAS-BLED score, although there are other scores that recognized female sex as a risk factor for bleeding. 17, 18 In the patients of the present study, the rate of major hemorrhage in those aged Ն75 years was 4.2% per year, which was higher than the whole population (3.6%/y) and almost twice that seen in patients aged Ͻ75 years (2.5%/y). Several studies have shown that elderly patients are at greater risk of bleeding. 6, 16, 19 , Nonetheless, OAC is still the most effective therapy for reducing stroke, and of note, OAC is associated with similar rates of major bleeding to antiplatelet therapy, particularly among elderly patients. 20, 21 We did not identify concomitant OAC and aspirin intake as a bleeding risk factor in the study population perhaps because of small numbers. Similar to the HEMORR 2 AGES (hepatic or renal disease; ethanol use; malignancy; older [age Ͼ75]; reduced platelet count or function; hypertension, uncontrolled; anemia; genetic factors; elevated risk of fall, including neuropsychiatric disease; stroke) scheme and Kuijer risk score, 17, 22 we also identified a history of malignancy as a risk factor for bleeding. It is important to note that none of the patients in the present study was having chemotherapy or radiotherapy, and their expected survival was Ͼ6 months.
Both the CHADS 2 and HAS-BLED scores were able to identify patients at risk of bleeding, with an HR of 1.96 and 1.23, respectively. Indeed, patients with a low CHADS 2 score (eg, 0 -1) have a lower major bleeding risk than those patients with CHADS 2 Ն2. Of note, bleeding rates only exceeded thrombotic events at an HAS-BLED score Ͼ3 and support recommendations in current guidelines for caution and regular review in patients with an HAS-BLED score Ն3. 8 Indeed, because of their high thromboembolic and cardiovascular risk, OAC medications are not contraindicated per se, as the risk-benefit ratio could potentially be worse if the patients were untreated.
Interestingly, the C statistics in predicting bleeding events were similar for both the HAS-BLED score and the multivariate analysis, essentially showing that the HAS-BLED score, although simple, performed as good as a multivariate analysis in the present study population. Indeed, the HAS-BLED score is simple and practical, whereas a multivariate analysis model is more complex and not useful for everyday clinical practice.
HAS-BLED Predicts Cardiovascular Events and Mortality
We also demonstrate that an HAS-BLED score Ն3 is a risk factor for cardiovascular events and mortality, which are end points significantly influenced by OAC therapy. For example, according to a meta-analysis by Hart et al, 3 OAC not only reduces stroke compared with placebo or control, but also significantly reduces cardiovascular events and mortality, whereas among elderly patients, OAC has an increased absolute benefit on stroke and cardiovascular events with increasing age, at the cost of a small increase in serious bleeding events. 21 Of note, we have previously described the ability of the CHADS 2 score to predict cardiovascular events in stable anticoagulated patients with AF, 14 and the strongest risk factors for cardiovascular events were age Ն75 years and acute heart failure. This is unsurprising given that the incidence of thrombotic events (including stroke, myocardial infarction, and vascular death) in an elderly anticoagulated AF population was 5.9% per year. 20 As expected, age Ն75 years, diabetes, heart failure, stroke, and malignant disease were also independent risk factors of all-cause mortality in the present study. As well, current smoking habit was found to be an independent risk factor of all-cause mortality in our study population, consistent with other studies in non-AF populations. 23 Given the multifactorial nature of death and cardiovascular events, it is not surprising that the predictive power of the multivariate analysis was slightly better per se for cardiovascular events (C statistic, 0.66) and mortality (C statistic, 0.77) compared with the HAS-BLED score (C statistic, 0.58 and 0.62, respectively), although the 95% CIs for cardiovascular events overlapped with those derived for the multivariate analysis. Our hypothesis was not to prove that HAS-BLED is the most accurate score to predict death or cardiovascular events but to show how HAS-BLED can be related to both bleeding and thrombotic events, given the strong link between thrombotic and bleeding risk 6 -16 and, thus, to mortality. Additionally, the HAS-BLED score was designed to predict bleeding (and it does well in this analysis) rather than thrombotic events per se.
Finally, in the present analysis, we have validated the HAS-BLED score for the first time to our knowledge in consecutive Spanish patients taking acenocoumarol. Acenocoumarol is the most common vitamin K antagonist used in Spain, with its main difference from warfarin being related to the much shorter half-life of this drug (9 hours for acenocoumarol versus 36 -42 hours for warfarin 24 ), which is perceived to have some practical advantages in the clinical setting.
Clinical Implications
The main advantage of the HAS-BLED score is that it is simple and user friendly yet offers useful predictive capacity for bleeding. Additionally, the HAS-BLED was designed so that clinicians can think about the potentially correctable bleeding risk factors (controlling blood pressure [the H in HAS-BLED], avoiding concomitant aspirin and nonsteroidal antiinflammatory drug use [the D in HAS-BLED], etc). For an HAS-BLED score of Ն3, the HR for having a bleeding event is high at 3.68. Although the C statistics were modest, the HAS-BLED score was not designed to simply make clinicians stop prescribing OAC for patients with high scores but to identify patients who have to be more carefully managed and reviewed or to highlight the common correctable bleeding risk factors. Indeed, the net clinical benefit of balancing ischemic stroke against intracranial hemorrhage is even higher in patients with high HAS-BLED scores given that the absolute beneficial reduction in ischemic stroke with anticoagulation would exceed the much smaller absolute increase in serious hemorrhage. 25 Additionally, the HAS-BLED score was not designed as a predictor of thromboembolic events (where other scores, eg, CHADS 2 or CHA 2 DS 2 -VASc, have been well validated) or mortality. This aspect is shown by the differences in C statistics and by our multivariate analysis. Nonetheless, the present study shows the close relationship between thrombosis and bleeding events, drawing attention to the management of those patients at high risk of both.
Limitations
There could be a selection bias because patients were steady at entry, so unstable patients who are more prone to have adverse events were excluded. Similarly, they were all "experienced" patients with coumarin treatment. It is known that the risk of bleeding on anticoagulant therapy or having a thromboembolic event is highest during the period immediately after coumarins are initiated. 26 Although TTR on admission was 100%, we did not have details on TTR over the follow-up period. Most studies (even clinical trials) manage TTR rates of between 60% and 75%, and thus, our cohort may not represent real-life patients. Indeed, TTR has a significant relationship with adverse outcomes, and with good INR control, bleeding risk is lowest. 27 However, the strength of our study is its inclusion of consecutive patients attending our anticoagulation clinic, and even when reducing 1 point on the HAS-BLED score, it still maintained its predictive power on bleeding events. We also performed follow-up by mainly reviewing clinical records and conducting phone interviews with patients.
Conclusions
We demonstrate the predictive value and usefulness of the HAS-BLED score for predicting major bleeding in a large cohort of consecutive patients taking acenocoumarol. We also demonstrate the close relationship between thrombosis and bleeding and show that the HAS-BLED score has predictive value for cardiovascular events and mortality. This simple risk score can be used in everyday clinical practice as an easy risk assessment in anticoagulated patients with AF.
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